- Conditions
- Narcolepsy
- Interventions
- SUVN-G3031, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 5,286
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 404
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
- Conditions
- Acute Pancreatitis
- Interventions
- Not listed
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 390
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
- Conditions
- Cervical Dystonia
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
- Conditions
- Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
- Interventions
- ALK-001 oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
- Conditions
- Reasoning Training
- Interventions
- Telehealth Reasoning Training
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Low Back Pain
- Interventions
- Bupivacaine TTS (Bupivacaine Patch), Placebo patch
- Drug
- Lead sponsor
- Durect
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- Tempe, Arizona • La Mesa, California • Torrance, California + 18 more
- Conditions
- Cystic Fibrosis
- Interventions
- CF with culturable NTM
- Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 8 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Epilepsy
- Interventions
- RNS® System
- Device
- Lead sponsor
- NeuroPace
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Acute Kidney Injury (AKI)
- Interventions
- ASP1128, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
- Conditions
- Anxiety, Generalized Anxiety Disorder, Sleep Problems
- Interventions
- Hemp Derived Cannabidiol Extract, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pharmacokinetics
- Interventions
- Low furanocoumarin hybrid grapefruit juice, Regular grapefruit juice, Water (control)
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
- Interventions
- Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
- Interventions
- Ad26.COV2.S, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44,325 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- RGX-202
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 1 Year and older · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Lidoderm, Celecoxib
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 20
- States / cities
- Hueytown, Alabama • Mesa, Arizona • Oro Valley, Arizona + 17 more
- Conditions
- Pain, Postoperative
- Interventions
- single-arm study group
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Congestive Heart Failure
- Interventions
- MyoCell, Hypothermosol
- Biological · Procedure
- Lead sponsor
- Bioheart, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Iza-bren, Carboplatin, Cisplatin, Pemetrexed, Amivantamab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 661 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 28
- States / cities
- Irvine, California • Orange, California • Edwards, Colorado + 22 more
- Conditions
- Hepatocellular Cancer
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Dyslexia
- Interventions
- active taVNS, sham taVNS
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida